S
System1 Biosciences
Neurotherapeutics company leveraging human brain models, scaled biology, and machine learning to discover novel drugs for complex brain diseases
About System1 Biosciences
System1 Biosciences, Inc. is a San Francisco-based neurotherapeutics company focused on discovering novel drugs for complex neurological and psychiatric diseases. The company employs phenotypic screening, which involves observing the effects of potential drugs on disease models, to identify promising therapeutic candidates. System1 Biosciences uses human stem cell-derived organoid models of brain tissue to capture disease-relevant genetics and target specific cell types, providing a more accurate representation of human brain diseases. Automation plays a crucial role in their approach, enabling scaled biology through automated culture and assay systems. This allows for high-throughput screening and more efficient drug discovery processes. Additionally, the company integrates advanced machine learning analytics to refine and augment the drug discovery process, from target identification to Investigational New Drug (IND) application. System1 Biosciences serves the pharmaceutical and biotechnology sectors, focusing on clients looking for innovative solutions to treat brain diseases. The company operates in the neurotherapeutics market, which is characterized by a high unmet need for effective treatments. The business model involves partnering with pharmaceutical companies and research institutions to develop and commercialize their drug candidates. Revenue is generated through research collaborations, licensing agreements, and milestone payments.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- San Francisco, United States
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 25.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2018 | $25M | $100M | CRV | — |
Growth signals
Latest recorded traffic for System1 Biosciences is 280 monthly website visits, up 0% over the last three months. System1 Biosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Other known investors2 additional known investors
Dolby Family Ventures
Longevity Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about System1 Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See System1 Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.